Abstract:Mononucleosomal ctDNA (mnctDNA, 157-bp, double-stranded) spearheads liquid biopsy (LB) for cancer detection, treatment and clinical care. The bottleneck of mnctDNA LB are low copy number of ctDNA and limit of detection of platform technologies. Recent discovery of ultra-short ctDNA (usctDNA, 52-54 nt, single-stranded) that harbors somatic mutations prompted us to explore the quantification and stoichiometry of usctDNA to mnctDNA in plasma and saliva of NSCLC patients. Paired plasma and saliva from 20 advanced NSCLC patients with tissue genotyped positive for L858R were processed for cfDNA extraction and quantification with Qubit and Tape Station. Digital PCR assays targeting L858R somatic mutation to generate amplicons of 57-bp (usctDNA) and 100-bp (mnctDNA) were performed by UCLA and independently by NIST. Results in Table 1 revealed that three findings of usctDNA that will have potential to impact ctDNA liquid biopsy. First, the somatic mutation (L858R) is present in usctDNA. Second, The stoichiometric ratio of usctDNA to mnctDNA is similar in plasma and saliva at 1.6X. For the wild-type counterpart, the ratio is 1.1X for plasma and 0.6X for saliva. Third, the copy number of usctDNA and mnctDNA in saliva to plasma is 7.8X and 7.7X. Conclusion: Detection of tumor-associated/specific EGFR L858R somatic mutations in uscfDNA is translationally impactful, adding 1.6X of the ctDNA targets for molecular detection, effectively cumulating 2.6X of total ctDNA targets, permitting earlier cancer detection, treatment monitoring and therapy prognostication. The finding that saliva harbors 7X of the us- and mnctDNA further raises the prospect of advancing saliva ctDNA liquid biopsy for NSCLC detection as it may effectively allow 15.5X (7.8X+7.7X) ability to detect malignancy-associated ctDNA. Table 1. Quantification of usctDNA and mnctDNA in Plasma and Saliva Mut usctDNA (L858R) WT cfDNA usctDNA mnctDNA U/M uscfDNA mncfDNA U/M Plasma 1555 ± 326 964 ± 209 1.6X 15201 ± 1509 13261 ± 1424 Saliva 12158 ± 1731 7442 ± 1020 1.6X 340896 ± 27170 601733 ± 71573 1.1X Saliva/Plasma (fold X) 7.8 7.7 1.6X 22.4 45.3 0.6X Citation Format: Feng Li, Fang Wei, Hua-Jun He, Chien-Chung Lin, Szu-Chun Yang, Allen Wei-Lun Huang, Cheuk Ying Tang, Yong Kim, David T. Wong. Ultra-short ctDNA: A new paradigm for ctDNA liquid biopsy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB106.

EFIRM Liquid Biopsy (elb): Detection of Ultra-Short Circulating Tumor DNA (usctdna) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients.

Ultra-Short Circulating Tumor DNA (usctdna) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients.

Electric Field-Induced Release and Measurement (EFIRM) <i>Characterization and Technical Validation of a Novel Liquid Biopsy Platform in Plasma and Saliva</i>

Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment.

P1.11-13 Noninvasive Detection of Early Stage NSCLC EGFR Mutations Using Electric Field Induced Release and Measurement (EFIRM)

Technical Validation Of The Electric Field-Induced Release And Measurement (Efirm) Assay For The Detection Of Egfr Mutations In Circulating Cell Free Dna In Plasma And Saliva.

Single-Droplet Microsensor for Ultra-Short Circulating EFGR Mutation Detection in Lung Cancer Based on Multiplex EFIRM Liquid Biopsy

Evaluation of a Novel Saliva-Based Epidermal Growth Factor Receptor Mutation Detection for Lung Cancer: A Pilot Study.

Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports

Ultra-short Circulating Tumor DNA (usctdna): A New Paradigm for Ctdna Liquid Biopsy

Noninvasive Saliva-based EGFR Gene Mutation Detection in Patients with Lung Cancer

Abstract LB106: Ultra-short ctDNA: A new paradigm for ctDNA liquid biopsy

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Multiplex Picoliter-Droplet Digital PCR for Quantitative Assessment of EGFR Mutations in Circulating Cell-Free DNA Derived from Advanced Non-Small Cell Lung Cancer Patients

Liquid Biopsies Using Pleural Effusion-Derived Exosomal DNA in Advanced Lung Adenocarcinoma.

Detection and Dynamic Changes of Egfr Mutations from Circulating Tumor Dna As A Predictor of Survival Outcomes in Nsclc Patients Treated with First-Line Intercalated Erlotinib and Chemotherapy

Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR Based Method As a Diagnostic Biomarker for Non-Small Cell Lung Cancer.

447PD Modified Ctdna Extraction Method Combined with Blocker PCR Assays Improves the Liquid Biopsy Efficiency in NSCLC Patients

Assessment of EGFR Mutations in Plasma from Advanced NSCLC Patients by Modified Cell-Free DNA Extraction Method and Blocker PCR Assays

P1.01-27 Serial Circulating Tumor DNA (ctdna) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC

Saliva-derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non-small cell lung cancer.